Baidu
map

2015版中国药典发布,附7大变化清单

2015-06-11 佚名 赛柏蓝

6月10日,国家药典委员会发布公告,称根据《中华人民共和国药品管理法》,《中华人民共和国药典》(2015年版,以下简称药典)经第十届药典委员会执委会全体会议审议通过,予以发布,自2015年12月1日起实施。药典是药品行业的最重要的文件之一,其修改一直备受瞩目。2015年版是继我国1953年第一版药典以来的第十版药典。公开资料显示,2015年2月4日,第十届药典委员会执行委员会全体会议审议并通过了《

6月10日,国家药典委员会发布公告,称根据《中华人民共和国药品管理法》,《中华人民共和国药典》(2015年版,以下简称药典)经第十届药典委员会执委会全体会议审议通过,予以发布,自2015年12月1日起实施。

药典是药品行业的最重要的文件之一,其修改一直备受瞩目。2015年版是继我国1953年第一版药典以来的第十版药典。

公开资料显示,2015年2月4日,第十届药典委员会执行委员会全体会议审议并通过了《中国药典》2015年版草案。

药典委员会副主任委员、国家食品药品监管总局吴浈副局长做了会议总结,他指出,2015年版药典无论是在药典品种收载、标准增修订幅度、检验方法完善、检测限度设定,还是在标准体系的系统完善、质控水平的整体提升都上了一个新的台阶。

《中国药典》的颁布实施体现了我国的用药水平、制药水平和监管水平。因此,要不断加强药典标准工作,发挥其引领和规范作用。下一版的药典将是2020年版,要认真做好2020年版药典的规划工作,使2020年版药典水平再上新台阶。

药典七大变化清单

在中国药典2015的后期编制时,国家药典委员会秘书长张伟曾经介绍了2015版药典主要有七个方面的变化,由于张伟介绍时仍然不是最终定稿,所以这个方面的变化中,一些具体数字可能会有所变化,但是整体精神仍可供参考。

一是收载品种增幅达到27.4%。2015版药典拟收载5800个品种,比2010版药典增加1200多个,修订品种751个。(此数字是否是最终数字,有待业内人士指正)。

二是通过药典凡例、通则、总论的全面增修订,从整体上进一步提升了对药品质量控制的要求,完善了药典标准的技术规定,使药典标准更加系统化、规范化。

三是健全了药品标准体系。特别是药用辅料品种增加至260个(赛柏蓝注:最终公布270种,增加幅度更大),新增相关指导原则;在归纳、验证和规范的基础上实现了《中国药典》各部共性检测方法的协调统一。

四是2015版药典附录(通则)、辅料独立成卷,构成《中国药典》四部的主要内容。

五是药用辅料品种收载数量显著增加。拟新增128个,共计260个,增长率高达97%。(赛柏蓝注:最终公布270种,增加幅度更大)

六是安全性控制项目大幅提升。

中药:制定了中药材及饮片中二氧化硫残留量限度标准,推进建立和完善重金属及有害元素、黄曲霉毒素、农药残留量等物质的检测限度标准;加强对重金属以及中药材的有毒有害物质的控制等。

化学药:有关物质加强了杂质定性和定量测定方法的研究,实现对已知杂质和未知杂质的区别控制,优化抗生素聚合物测定方法,设定合理的控制限度,整体上进一步提高有关物质项目的科学性和合理性等。

生物制品:增加相关总论的要求,严格生物制品全过程质量控制要求,以保证产品的安全有效性,同时增订“生物制品生产用原辅材料质量控制通用性技术要求”,加强源头控制,最大限度降低安全性风险等。

七是进一步加强有效性控制。中药材加强了专属性鉴别和含量测定项设定。化学药适当增加了控制制剂有效性的指标,研究建立科学合理的检查方法。生物制品进一步提高效力测定检测方法的规范性,加强体外法替代体内法效力测定方法的研究与应用,保证效力测定方法的准确性和可操作性。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=29427, encodeId=13fe2942ef6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540017, encodeId=2642154001e75, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Sat Jun 13 06:52:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27230, encodeId=8e212e230d0, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5c31627260, createdName=Darcy2500, createdTime=Thu Jun 11 23:46:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27177, encodeId=1c4c2e177ea, content=药品安全人重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27178, encodeId=eb372e1781b, content=应该加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27055, encodeId=32192e05553, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=069c1625309, createdName=I+am+super, createdTime=Thu Jun 11 18:05:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27036, encodeId=98bc2e03623, content=用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:03:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=29427, encodeId=13fe2942ef6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540017, encodeId=2642154001e75, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Sat Jun 13 06:52:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27230, encodeId=8e212e230d0, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5c31627260, createdName=Darcy2500, createdTime=Thu Jun 11 23:46:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27177, encodeId=1c4c2e177ea, content=药品安全人重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27178, encodeId=eb372e1781b, content=应该加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27055, encodeId=32192e05553, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=069c1625309, createdName=I+am+super, createdTime=Thu Jun 11 18:05:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27036, encodeId=98bc2e03623, content=用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:03:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-13 lsj632
  3. [GetPortalCommentsPageByObjectIdResponse(id=29427, encodeId=13fe2942ef6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540017, encodeId=2642154001e75, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Sat Jun 13 06:52:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27230, encodeId=8e212e230d0, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5c31627260, createdName=Darcy2500, createdTime=Thu Jun 11 23:46:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27177, encodeId=1c4c2e177ea, content=药品安全人重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27178, encodeId=eb372e1781b, content=应该加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27055, encodeId=32192e05553, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=069c1625309, createdName=I+am+super, createdTime=Thu Jun 11 18:05:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27036, encodeId=98bc2e03623, content=用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:03:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 Darcy2500

    棒棒哒

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=29427, encodeId=13fe2942ef6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540017, encodeId=2642154001e75, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Sat Jun 13 06:52:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27230, encodeId=8e212e230d0, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5c31627260, createdName=Darcy2500, createdTime=Thu Jun 11 23:46:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27177, encodeId=1c4c2e177ea, content=药品安全人重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27178, encodeId=eb372e1781b, content=应该加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27055, encodeId=32192e05553, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=069c1625309, createdName=I+am+super, createdTime=Thu Jun 11 18:05:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27036, encodeId=98bc2e03623, content=用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:03:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 18619c0a62m

    药品安全人重要

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=29427, encodeId=13fe2942ef6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540017, encodeId=2642154001e75, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Sat Jun 13 06:52:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27230, encodeId=8e212e230d0, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5c31627260, createdName=Darcy2500, createdTime=Thu Jun 11 23:46:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27177, encodeId=1c4c2e177ea, content=药品安全人重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27178, encodeId=eb372e1781b, content=应该加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27055, encodeId=32192e05553, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=069c1625309, createdName=I+am+super, createdTime=Thu Jun 11 18:05:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27036, encodeId=98bc2e03623, content=用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:03:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 18619c0a62m

    应该加强

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=29427, encodeId=13fe2942ef6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540017, encodeId=2642154001e75, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Sat Jun 13 06:52:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27230, encodeId=8e212e230d0, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5c31627260, createdName=Darcy2500, createdTime=Thu Jun 11 23:46:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27177, encodeId=1c4c2e177ea, content=药品安全人重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27178, encodeId=eb372e1781b, content=应该加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27055, encodeId=32192e05553, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=069c1625309, createdName=I+am+super, createdTime=Thu Jun 11 18:05:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27036, encodeId=98bc2e03623, content=用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:03:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 I+am+super

    了解

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=29427, encodeId=13fe2942ef6, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:50:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540017, encodeId=2642154001e75, content=<a href='/topic/show?id=384d8e3195a' target=_blank style='color:#2F92EE;'>#药典#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87319, encryptionId=384d8e3195a, topicName=药典)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83f713173950, createdName=lsj632, createdTime=Sat Jun 13 06:52:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27230, encodeId=8e212e230d0, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=229, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5c31627260, createdName=Darcy2500, createdTime=Thu Jun 11 23:46:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27177, encodeId=1c4c2e177ea, content=药品安全人重要, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27178, encodeId=eb372e1781b, content=应该加强, beContent=null, objectType=article, channel=null, level=null, likeNumber=192, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Thu Jun 11 21:10:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27055, encodeId=32192e05553, content=了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=069c1625309, createdName=I+am+super, createdTime=Thu Jun 11 18:05:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27036, encodeId=98bc2e03623, content=用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Thu Jun 11 17:03:00 CST 2015, time=2015-06-11, status=1, ipAttribution=)]
    2015-06-11 qinweihan19

    用药是大学问

    0

相关资讯

解读:2015版药典主要的七个方面变化

导读:近日,国家药典委员会秘书长张伟在“2014年注射剂工业大会”上表示,2015版《中国药典》(以下简称2015版药典)编制工作已进入后期阶段。按照编制大纲确定的目标和“进度服从质量”的原则,各项工作稳步推进。 从总体情况看,2015版药典收载品种的安全性、有效性以及质量控制水平又有了新的提高,基本实现了“化学药、生物药达到或接近国际标准,中药主导国际标准”的总目标。 七大变化提升总

Baidu
map
Baidu
map
Baidu
map